SCS
BHVN

Syquant Capital SAS’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Syquant Capital SAS’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$3.02M – 31
2022
Q3 		$3.02M Buy
+20,000
New +$2.96M 1.84% 11

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Syquant Capital SAS's BHVN Position: Q4 2022 in Review

Syquant Capital SAS sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 20,000 shares — an estimated $3.02M sold.

Syquant Capital SAS first reported a position in BHVN in Q3 2022 and held it in 1 quarter. The position peaked at $3.02M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Syquant Capital SAS reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Syquant Capital SAS sold 20,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $3.02M.
  • Syquant Capital SAS first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022 and held it in 1 quarter.
  • Syquant Capital SAS's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.02M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Syquant Capital SAS's 13F filing for Q4 2022, filed 17 Jan 2023.